Founded in 2016, Maxwell Biosciences is a preclinical drug platform company that develops biomimetic therapeutics – synthetic compounds that mimic and improve upon natural peptides. Inspired by nature, these small molecules are created by Maxwell’s exclusive, first-in-class CLAROMER™ drug discovery platform and have been shown to be effective in destroying viruses, bacteria, fungi and biofilms with a single compound, while safely avoiding healthy cells. This “One Drug for Many Bugs” technology has been shown to be well-tolerated in human tissues in vitro, and in multiple animal studies. The compounds imitate key components of the immune system, humanity’s greatest asset in fighting disease. Maxwell’s technology is protected by numerous granted and pending patents and is led by a world-class team of experienced life science executives. To learn more about Maxwell Biosciences, visit MaxwellBiosciences.com, or follow us on Twitter and LinkedIn.
